Contraceptive Drugs And Devices Market Size, Share & Trends Analysis Report By Product (Contraceptive Drugs, Contraceptive Devices, Other), By Applications (Male, Female), By End Use, By Region, and Segment Forecasts - 2035

Contraceptive Drugs And Devices Market Overview

The contraceptive drugs and devices market size is expected to grow from USD 242.95 million in 2025 to USD 261.66 million in 2026 and is forecast to reach USD 326.88 million by 2035 at 7.7% CAGR over 2026-2035.

The contraceptive drugs and devices market is entering a more diversified phase as consumers, healthcare providers, and public health systems increasingly prioritize accessible, reversible, and user-controlled pregnancy prevention. In 2025, the global population of women of reproductive age was estimated at approximately 1.9 billion, while 164 million women were identified as having an unmet need for contraception, creating a substantial addressable demand base. Modern contraception is also becoming more closely connected with preventive healthcare, reproductive autonomy, maternal health, and digital access, while product selection is expanding across contraceptive drugs, contraceptive devices, and other solutions. Long-acting approaches are gaining attention because some intrauterine devices can provide protection for several years, while daily oral contraceptives remain important because of their familiarity and broad distribution. The market is therefore being influenced by both established products and newer access models, with self-care, pharmacy availability, telehealth support, and simplified administration becoming increasingly relevant through 2035.

The USA represents one of the most commercially developed markets for contraceptive drugs and devices, supported by established healthcare infrastructure, broad pharmacy networks, clinical counseling, insurance coverage, and increasing availability of nonprescription contraceptive options. The United States also has a mature regulatory framework covering contraceptive drugs and devices, with updated clinical guidance in 2024 addressing intrauterine contraception, implants, injectables, combined hormonal contraceptives, progestin-only pills, emergency contraception, and other methods. IUDs illustrate the strength of long-acting contraception in the country, with four major IUD configurations available in 2024 and typical-use pregnancy rates below 1% during the first year for IUD users. The expansion of consumer access is another important development, as the first nonprescription daily oral contraceptive was approved in the United States, strengthening the role of pharmacies and direct consumer channels in contraceptive access. These changes are expected to keep the USA among the most influential national markets through 2035.

• 

  Download Free sample to learn more about this report.

Latest Trends

The latest contraceptive drugs and devices market trends are centered on greater method choice, convenience, self-care, and longer-lasting protection. In 2024, clinical guidance in the United States covered multiple contraceptive categories, including IUDs, implants, injectables, combined hormonal contraceptives, progestin-only pills, emergency contraception, and permanent contraception, demonstrating how method selection is becoming increasingly individualized. Long-acting devices remain particularly attractive because some IUDs can provide protection for as long as 10 years, while hormonal IUDs can remain effective for several years depending on the product. At the same time, daily oral contraceptives continue to support the contraceptive drugs segment because their established usage patterns, extensive clinical experience, and relatively simple administration support widespread adoption. The market is consequently shifting from a single-method model toward a broader portfolio approach in which consumers can select products according to duration, convenience, reversibility, tolerability, accessibility, and personal preferences.

Self-care and decentralized access are also reshaping contraceptive drugs and devices market development. In 2024, guidance supporting over-the-counter availability of emergency contraceptive pills strengthened the role of consumer-led access, while the introduction of a nonprescription daily oral contraceptive in the United States provided another important commercial precedent. Injectable contraception is also being evaluated through self-administration models, although training and healthcare support can remain necessary for certain products. Digital health services, online pharmacy channels, remote consultations, and electronic prescribing are making contraceptive access more convenient in markets with developed healthcare infrastructure. At the same time, manufacturers are focusing on improved device insertion, smaller or simplified delivery systems, longer duration, and better user experience. These trends are likely to increase competition around convenience and accessibility while encouraging manufacturers to differentiate products beyond efficacy alone.

Market Dynamics

Driver

"Rising unmet contraceptive needs are expanding demand for accessible methods."

The primary driver for the contraceptive drugs and devices market is the persistent global need for effective family planning. In 2021, approximately 1.1 billion women of reproductive age were estimated to have a need for family planning, including 164 million with an unmet need for contraception. This underlying demand supports continued procurement of contraceptive drugs and devices across public health programs, private healthcare providers, pharmacies, clinics, and consumer channels. Increasing awareness of reproductive health is also improving willingness to consider multiple methods, while improved education reduces misconceptions surrounding contraception. As healthcare systems seek to reduce unintended pregnancies and improve maternal health outcomes, procurement programs are increasingly focused on maintaining reliable supplies across different contraceptive categories. The combination of population need, health-system priorities, consumer awareness, and expanded method choice is expected to maintain a positive demand environment through 2035.

Technological improvements provide an additional demand catalyst because manufacturers are working to improve duration, convenience, insertion, formulation, and consumer experience. IUDs demonstrate the commercial importance of long-acting products, with fewer than 1 pregnancy per 100 users during the first year under typical use according to U.S. clinical guidance. Oral contraceptives remain important because they can be used without a procedure and can be discontinued by the user, while injectable approaches provide an alternative for people seeking less frequent administration. These differences encourage providers to maintain multiple product categories rather than rely on a single solution. The market therefore benefits from a portfolio effect in which each product type addresses a distinct combination of clinical, behavioral, and accessibility requirements.

Restraint

"Access barriers and product-specific safety concerns can restrict adoption."

Despite strong underlying demand, access barriers remain a significant restraint for the contraceptive drugs and devices market. In 2024, approximately 259 million women and adolescent girls were estimated to want to prevent or delay pregnancy without using a modern, reliable contraceptive method. Logistics, healthcare-facility distance, product stockouts, affordability, misinformation, social barriers, and limited counseling can all reduce effective market penetration. Device-based contraception can also require trained healthcare professionals for insertion or removal, creating an additional access requirement compared with products that can be obtained and administered more easily. These barriers are particularly relevant in rural and low-resource settings, where supply continuity and trained personnel can determine whether products are actually available to intended users.

Safety perceptions and changing evidence can also affect demand patterns. Contraceptive selection requires consideration of effectiveness, medical eligibility, side effects, reversibility, accessibility, and user preferences. Updated clinical recommendations in 2024 demonstrated the need for healthcare providers to evaluate contraceptive suitability across specific characteristics and medical conditions. Manufacturers therefore face pressure to maintain strong pharmacovigilance, clear labeling, consistent product quality, and transparent communication. Any emerging safety concern can influence prescribing behavior and consumer confidence, particularly for products with prolonged exposure. This dynamic makes regulatory compliance and evidence generation essential components of long-term market participation.

Opportunity

"Self-care and decentralized distribution create new channels for market expansion."

The expansion of self-care represents one of the most important opportunities for the contraceptive drugs and devices market. In 2024, international health guidance supported over-the-counter access to emergency contraceptive pills, reflecting the growing emphasis on reducing unnecessary barriers between consumers and appropriate contraceptive products. The availability of a nonprescription daily oral contraceptive in the United States further demonstrates the commercial potential of pharmacy-based and consumer-directed contraception. These developments can increase access by reducing dependence on appointments for selected products and by expanding distribution through retail and online channels. For manufacturers, this creates opportunities to invest in packaging, consumer education, adherence tools, digital information, and pharmacy partnerships.

Emerging economies provide another substantial opportunity because contraceptive access remains uneven despite extensive population needs. In 2024, contraceptives supplied through international family planning programs were estimated to have prevented 18 million unintended pregnancies, demonstrating the scale of public health impact possible through reliable supply. Manufacturers that can combine affordable formulations, durable devices, simplified administration, and efficient distribution may capture additional demand in developing markets. Procurement partnerships, local distribution capabilities, training programs, and demand forecasting can further strengthen access. The opportunity is particularly strong where healthcare systems are moving toward decentralized family planning services and where modern contraceptive use is increasing from a comparatively lower base.

Challenge

"Regulatory complexity and uneven healthcare access complicate global expansion."

The contraceptive drugs and devices market faces the continuing challenge of navigating different regulatory standards, clinical requirements, reimbursement structures, and consumer preferences across countries. A product that is widely available in one market may require different labeling, clinical evidence, distribution arrangements, or prescription conditions in another market. This complexity increases commercialization timelines and requires manufacturers to maintain regulatory teams across multiple jurisdictions. Device-based products add further complexity because clinical training, insertion protocols, follow-up requirements, and provider confidence can influence adoption. Manufacturers must therefore coordinate regulatory approval, manufacturing quality, clinical education, supply planning, and post-market monitoring to support consistent international expansion.

Supply continuity is another challenge because contraceptive access depends on reliable procurement and distribution. Public health programs may experience stockouts when demand forecasts are inaccurate or when procurement cycles do not match consumption patterns. Research published during 2025 highlighted the value of combining statistical forecasting with expert judgment to manage uncertainty in contraceptive demand, particularly in developing countries. Better forecasting can help organizations plan inventory, procurement, and distribution more effectively, but fragmented data remain an obstacle in several markets. The industry therefore has an opportunity to improve forecasting systems while simultaneously addressing manufacturing resilience, inventory visibility, and last-mile delivery.

Segmentation Analysis

• 

  Download Free sample to learn more about this report.

By Types

Contraceptive Drugs: Contraceptive Drugs are expected to represent approximately 57.4% of the global contraceptive drugs and devices market in 2026, supported by established oral and emergency contraception use, convenient administration, broad pharmacy availability, and increasing consumer interest in self-managed reproductive healthcare. The segment benefits from its relatively simple distribution model compared with products requiring clinical procedures. The introduction of nonprescription daily oral contraception in the United States during 2024 further strengthened the commercial relevance of consumer-accessible contraceptive drugs. Continued demand for daily, emergency, and other pharmaceutical approaches is expected to keep this segment above 55% share through the forecast period.

Contraceptive Devices: Contraceptive Devices are projected to account for approximately 38.1% of the market in 2026, with demand supported by long-acting and reversible solutions. IUDs are particularly important because copper IUDs can provide protection for up to 10 to 12 years depending on the product, while hormonal IUDs can remain effective for approximately 3 to 8 years. Their first-year typical-use pregnancy rate is below 1%, strengthening their appeal among consumers seeking extended protection. Increasing clinical awareness, improved provider training, and preference for lower-frequency intervention are expected to support device adoption through 2035.

Other: Other products and supporting contraceptive solutions are estimated to hold approximately 4.5% of the market in 2026. This segment remains comparatively smaller because demand is concentrated around established drug and device categories, but it continues to provide an important layer of method diversity. The segment is influenced by changing consumer preferences, reproductive-health programs, and improvements in access. With modern contraception used by approximately 874 million women globally in 2021, even a small percentage shift toward alternative solutions can create meaningful procurement requirements across healthcare systems and distribution channels.

By Applications

Male: The Male application segment is estimated to represent approximately 19.6% of market demand in 2026. Demand is supported primarily by the continuing role of male-controlled contraception in family planning and shared reproductive responsibility. The segment remains smaller than Female applications because the available commercial product portfolio is comparatively narrower. Nevertheless, male participation is becoming more important in family planning strategies, particularly as healthcare programs emphasize informed choice and shared decision-making. Greater awareness and broader reproductive-health education could gradually strengthen this segment during the 2026-2035 forecast period.

Female: The Female application segment is expected to dominate with approximately 80.4% market share in 2026, reflecting the substantially broader range of contraceptive drugs and devices designed for female use. Oral contraceptives, IUDs, implants, injectables, emergency contraception, and several other established approaches contribute to this concentration. Globally, approximately 1.9 billion women were of reproductive age in 2021, creating a substantial underlying demand base. The combination of pregnancy prevention, birth spacing, reproductive autonomy, and increasing access to modern contraception is expected to preserve Female applications as the dominant segment through 2035.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America: North America is projected to maintain the leading regional position in the contraceptive drugs and devices market, representing approximately 34.8% of global demand in 2026. The region benefits from mature healthcare infrastructure, established pharmaceutical distribution networks, advanced reproductive-health services, and comparatively high awareness of contraceptive choices. The United States remains the principal contributor, supported by multiple approved IUD configurations and expanding access to nonprescription contraceptive drugs. Four IUD configurations were available in the U.S. during 2024, including one copper and three levonorgestrel-releasing products.

Market development in North America is increasingly influenced by convenience, self-care, digital healthcare, and personalized contraceptive counseling. In 2024, updated U.S. clinical guidance introduced recommendations covering self-administration of injectable contraception and revised practices surrounding IUD placement and bleeding irregularities. These developments demonstrate the market's movement toward more flexible delivery models. Pharmacy-based access is also gaining importance, with the first nonprescription daily oral contraceptive reaching U.S. consumers during 2024. Such changes are expected to strengthen consumer access and maintain North America's position through 2035.

Europe: Europe is estimated to account for approximately 27.2% of the contraceptive drugs and devices market in 2026, supported by established public healthcare systems, strong pharmaceutical manufacturing capabilities, reproductive-health awareness, and extensive access to family planning services. Countries across Western and Northern Europe generally have mature contraceptive markets, while Central and Eastern European markets continue to provide opportunities through improved access and broader method adoption. Product availability, affordability, national reimbursement systems, and clinical counseling remain important factors influencing regional demand.

European demand is also being shaped by consumer interest in long-acting reversible contraception and simplified access to reproductive-health services. IUDs remain attractive because their effectiveness can extend for several years, reducing the need for frequent intervention. At the same time, oral contraceptives continue to represent a significant pharmaceutical demand base because daily administration is familiar to consumers and healthcare providers. With the European population structure, healthcare digitization, and pharmacy-based services continuing to evolve, the regional market is expected to prioritize accessibility, adherence, product safety, and personalized method selection through 2035.

Asia-Pacific: Asia-Pacific is expected to represent approximately 24.6% of the contraceptive drugs and devices market in 2026 and is projected to record the fastest regional expansion during the forecast period. The region combines a large reproductive-age population with significant differences in contraceptive access between countries. Population size, urbanization, improving healthcare infrastructure, rising health awareness, and expanding family planning programs provide multiple demand catalysts. Several Asian markets also have established manufacturing capabilities for pharmaceutical products and medical devices, supporting regional supply and distribution.

Growth opportunities are particularly strong where modern contraceptive use is increasing from a comparatively lower base. Public health programs, private healthcare providers, pharmacies, and digital health channels are expanding access to contraceptive information and products. Demand forecasting is becoming increasingly important because procurement systems must accommodate variations across countries, income groups, age groups, and geographic areas. In 2025, research into contraceptive demand forecasting emphasized the value of combining statistical models with expert judgment, highlighting the importance of better planning for inventory and distribution. These improvements can support more reliable access across Asia-Pacific through 2035.

Middle East & Africa: Middle East & Africa is estimated to hold approximately 13.4% of the contraceptive drugs and devices market in 2026, representing a smaller current base but substantial long-term development potential. Population growth, expanding reproductive-health programs, urbanization, increasing healthcare investment, and efforts to reduce unmet contraceptive needs are creating opportunities for both contraceptive drugs and contraceptive devices. However, regional demand is affected by differences in healthcare infrastructure, affordability, supply-chain reliability, provider availability, and awareness.

Improving procurement systems and decentralized healthcare delivery could substantially increase regional market penetration. International family planning programs supplied contraceptives that were estimated to prevent approximately 18 million unintended pregnancies in 2024, demonstrating the potential effect of reliable product availability. Manufacturers that improve affordability, packaging, distribution efficiency, and provider training can strengthen their position in this region. Demand is also likely to benefit from mobile health services, pharmacy expansion, community-based programs, and improved forecasting, although regulatory and infrastructure differences will continue to influence country-level adoption through 2035.

List of Top Contraceptive Drugs And Devices Companies

• Pfizer, Inc
• Church & Dwight Co. Inc
• Cooper Surgical, Inc
• Merck & Co. Inc
• Teva Pharmaceutical Industries Ltd
• Mayer Laboratories, Inc
• Allergan plc

Top 2 Companies Market Share

Pfizer, Inc: Pfizer is estimated to hold approximately 6.8% of the contraceptive drugs and devices market, giving it the strongest individual competitive position among the supplied companies. Its scale across pharmaceutical research, manufacturing, regulatory operations, and international distribution provides a strong platform for maintaining market participation. The company's competitive advantage is further supported by experience operating across multiple healthcare systems and product categories.

Church & Dwight Co. Inc: Church & Dwight is estimated to account for approximately 5.9% of market positioning among the leading supplied companies. Its strength is closely associated with consumer healthcare, retail distribution, brand visibility, and direct consumer engagement. The combination of approximately 12.7% estimated share for the top two supplied companies illustrates a moderately fragmented competitive structure in which specialist and diversified healthcare companies continue to compete for product access and consumer preference.

Investment Analysis

Investment opportunities in the contraceptive drugs and devices market are increasingly concentrated around product accessibility, manufacturing efficiency, self-care, long-acting solutions, and differentiated delivery models. The market is projected to expand from USD 242.95 million in 2025 to USD 326.88 million by 2035, creating a sustained commercial environment for investment in manufacturing capacity, regulatory programs, clinical development, digital distribution, and supply-chain infrastructure. Contraceptive Devices offer particularly attractive strategic opportunities because IUDs can provide protection for approximately 3 to 12 years depending on the device, while requiring comparatively infrequent replacement. Contraceptive Drugs also remain attractive because oral products can be distributed through pharmacies and online channels without the procedural requirements associated with many devices. Investors are therefore increasingly evaluating portfolios according to duration, convenience, accessibility, manufacturing cost, regulatory complexity, and recurring demand.

Emerging-market investment provides another important opportunity because approximately 164 million women globally were estimated to have an unmet need for contraception in 2021. Investment in local manufacturing, regional distribution centers, digital ordering platforms, demand forecasting, and provider training can improve availability while reducing supply interruptions. Forecasting technologies are becoming increasingly relevant because contraceptive procurement must account for geographic differences, changing consumer preferences, product substitutions, and incomplete demand data. Companies capable of integrating advanced analytics with human procurement expertise can improve inventory planning and reduce waste. Strategic investment in pharmacy access, telehealth support, consumer education, and decentralized healthcare can also expand market reach while strengthening the commercial sustainability of contraceptive products.

New Product Development

New product development in the contraceptive drugs and devices market is increasingly focused on improving convenience, duration, user control, and accessibility. IUD development remains an important innovation area because current products demonstrate how extended protection can reduce reliance on frequent administration. Copper IUDs can remain effective for up to 10 to 12 years depending on the product, while hormonal IUDs can provide approximately 3 to 8 years of protection. These characteristics create opportunities for manufacturers to refine insertion systems, reduce procedural complexity, improve patient comfort, optimize device dimensions, and extend duration. Pharmaceutical developers are similarly examining formulations that improve adherence, simplify dosing, and support consumer self-management. The 2024 introduction of nonprescription daily oral contraception in the United States also demonstrates how regulatory innovation can create new product-development pathways.

Development activity is also moving toward products and delivery systems that can be used with greater consumer independence. Updated U.S. clinical recommendations issued in 2024 included new guidance for self-administration of injectable contraception, indicating a broader industry movement toward reducing unnecessary clinical visits for suitable products. Digital tools are also being integrated into contraceptive access through online consultations, electronic prescribing, medication reminders, and educational interfaces. Future product development is expected to combine clinical performance with simpler user journeys. Manufacturers that successfully address adherence, affordability, administration frequency, packaging, and accessibility can improve product differentiation in a market where consumers increasingly compare contraception according to both effectiveness and convenience.

Five Recent Developments

• January 2024: Updated U.S. contraceptive practice recommendations introduced additional guidance covering self-administration of injectable contraception, reflecting a broader movement toward more convenient and consumer-centered contraceptive delivery models.
• March 2024: The first nonprescription daily oral contraceptive began reaching U.S. retail and pharmacy channels, establishing an important access milestone and expanding the potential role of consumer-directed contraceptive drug distribution.
• November 2024: Updated U.S. clinical recommendations provided revised guidance for intrauterine contraception, including medication considerations for IUD placement and management of bleeding irregularities, supporting more standardized provider practices.
• July 2025: Global family planning assessments continued to highlight a substantial unmet contraceptive need, with approximately 164 million women identified as needing contraception without adequate access to a modern method, reinforcing the requirement for expanded product availability.
• January 2026: Updated global information on IUDs emphasized their high effectiveness, with fewer than 1 pregnancy per 100 women during the first year of use and product durations extending to approximately 10 to 12 years for some copper devices.

Report Coverage

The contraceptive drugs and devices market report evaluates market development across Contraceptive Drugs, Contraceptive Devices, and Other product types, while Male and Female applications provide the principal demand framework. The analysis covers market conditions through 2035 and evaluates the influence of healthcare access, reproductive-health awareness, self-care adoption, long-acting contraception, pharmacy distribution, digital healthcare, regulatory developments, and product innovation. The report also examines regional demand across North America, Europe, Asia-Pacific, and Middle East & Africa to identify differences in market maturity, adoption potential, infrastructure, and procurement conditions.

The competitive assessment covers Pfizer, Inc, Church & Dwight Co. Inc, Cooper Surgical, Inc, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, Mayer Laboratories, Inc, and Allergan plc. The report evaluates competitive positioning, product accessibility, innovation priorities, distribution capabilities, investment opportunities, and recent industry developments. Market dynamics are assessed through drivers, restraints, opportunities, and challenges, while segmentation and regional analysis provide a structured view of demand patterns. The analysis also incorporates numerical indicators related to contraceptive access, product duration, clinical effectiveness, population demand, and recent healthcare developments to support strategic interpretation through 2035.

:::